NCT03958864View on ClinicalTrials.gov

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

June 13, 2019

Study Completion Date

June 13, 2019

Conditions
Healthy Volunteer
Interventions
DRUG

CC-90001

CC-90001

Trial Locations (1)

91206

Paraxel International, Glendale

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY